![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CALB2 |
Gene summary for CALB2 |
![]() |
Gene information | Species | Human | Gene symbol | CALB2 | Gene ID | 794 |
Gene name | calbindin 2 | |
Gene Alias | CAB29 | |
Cytomap | 16q22.2 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | A0A140VK08 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
794 | CALB2 | LZE4T | Human | Esophagus | ESCC | 3.98e-19 | 1.08e+00 | 0.0811 |
794 | CALB2 | P24T-E | Human | Esophagus | ESCC | 4.40e-09 | 4.41e-01 | 0.1287 |
794 | CALB2 | P26T-E | Human | Esophagus | ESCC | 4.40e-09 | 2.59e-01 | 0.1276 |
794 | CALB2 | P32T-E | Human | Esophagus | ESCC | 7.98e-13 | 1.01e+00 | 0.1666 |
794 | CALB2 | P37T-E | Human | Esophagus | ESCC | 3.33e-05 | 3.01e-01 | 0.1371 |
794 | CALB2 | P52T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.16e-01 | 0.1555 |
794 | CALB2 | P76T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.34e-01 | 0.1207 |
794 | CALB2 | P83T-E | Human | Esophagus | ESCC | 2.21e-33 | 1.38e+00 | 0.1738 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CALB2 | SNV | Missense_Mutation | c.443N>T | p.Asp148Val | p.D148V | P22676 | protein_coding | deleterious(0.02) | possibly_damaging(0.692) | TCGA-AR-A1AR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Docetaxel | PD | |
CALB2 | SNV | Missense_Mutation | novel | c.559C>G | p.Leu187Val | p.L187V | P22676 | protein_coding | deleterious(0) | possibly_damaging(0.646) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
CALB2 | insertion | Nonsense_Mutation | novel | c.799_800insTGAACTTTTAGTGTACCCATTTTACAG | p.Ser267delinsMetAsnPheTerCysThrHisPheThrGly | p.S267delinsMNF*CTHFTG | P22676 | protein_coding | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | ||
CALB2 | deletion | In_Frame_Del | c.204_206delNNN | p.Lys69del | p.K69del | P22676 | protein_coding | TCGA-D8-A143-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |||
CALB2 | SNV | Missense_Mutation | novel | c.236N>T | p.Ser79Leu | p.S79L | P22676 | protein_coding | tolerated(0.11) | benign(0.219) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CALB2 | SNV | Missense_Mutation | c.180N>C | p.Lys60Asn | p.K60N | P22676 | protein_coding | tolerated(0.43) | benign(0.222) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CALB2 | SNV | Missense_Mutation | c.180N>C | p.Lys60Asn | p.K60N | P22676 | protein_coding | tolerated(0.43) | benign(0.222) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CALB2 | SNV | Missense_Mutation | c.533G>T | p.Arg178Leu | p.R178L | P22676 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CALB2 | SNV | Missense_Mutation | c.368N>A | p.Arg123Lys | p.R123K | P22676 | protein_coding | tolerated(0.6) | possibly_damaging(0.777) | TCGA-AZ-6606-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folfiri | PD | |
CALB2 | SNV | Missense_Mutation | rs748994795 | c.283G>A | p.Glu95Lys | p.E95K | P22676 | protein_coding | deleterious(0.02) | possibly_damaging(0.636) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |